Cargando…
Brief review of the mRNA vaccines COVID-19
The global COVID-19 pandemic continues to claim victims worldwide, representing a health and socioeconomic challenge with few precedents in human history. The therapeutic agents used to treat COVID-19 infection are mostly aimed at avoiding the most serious complications and organ damage that in a pe...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087898/ https://www.ncbi.nlm.nih.gov/pubmed/33932192 http://dx.doi.org/10.1007/s10787-021-00811-0 |
_version_ | 1783686751972229120 |
---|---|
author | Vitiello, Antonio Ferrara, Francesco |
author_facet | Vitiello, Antonio Ferrara, Francesco |
author_sort | Vitiello, Antonio |
collection | PubMed |
description | The global COVID-19 pandemic continues to claim victims worldwide, representing a health and socioeconomic challenge with few precedents in human history. The therapeutic agents used to treat COVID-19 infection are mostly aimed at avoiding the most serious complications and organ damage that in a percentage of cases can be fatal. Recently, the first COVID-19 vaccines have been authorised, starting a massive vaccination campaign worldwide. The COVID-19 vaccines authorized or under testing use different methods of action such as mRNA, DNA vaccine, viral vector, protein subunit, and virus inactivated immunization strategies. The mRNA vaccines are the first authorised vaccines with this new method of action, initiating a new era of preventive medicine. To date, data indicate that they may be effective against the newly identified SARS-CoV-2 variants. Short-term studies indicated an acceptable safety profile but long-term immunity as well as safety is not yet available. In this article, we briefly describe mRNA vaccines and highlight some aspects yet to be fully defined. |
format | Online Article Text |
id | pubmed-8087898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-80878982021-05-03 Brief review of the mRNA vaccines COVID-19 Vitiello, Antonio Ferrara, Francesco Inflammopharmacology Short Communication The global COVID-19 pandemic continues to claim victims worldwide, representing a health and socioeconomic challenge with few precedents in human history. The therapeutic agents used to treat COVID-19 infection are mostly aimed at avoiding the most serious complications and organ damage that in a percentage of cases can be fatal. Recently, the first COVID-19 vaccines have been authorised, starting a massive vaccination campaign worldwide. The COVID-19 vaccines authorized or under testing use different methods of action such as mRNA, DNA vaccine, viral vector, protein subunit, and virus inactivated immunization strategies. The mRNA vaccines are the first authorised vaccines with this new method of action, initiating a new era of preventive medicine. To date, data indicate that they may be effective against the newly identified SARS-CoV-2 variants. Short-term studies indicated an acceptable safety profile but long-term immunity as well as safety is not yet available. In this article, we briefly describe mRNA vaccines and highlight some aspects yet to be fully defined. Springer International Publishing 2021-05-01 2021 /pmc/articles/PMC8087898/ /pubmed/33932192 http://dx.doi.org/10.1007/s10787-021-00811-0 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Short Communication Vitiello, Antonio Ferrara, Francesco Brief review of the mRNA vaccines COVID-19 |
title | Brief review of the mRNA vaccines COVID-19 |
title_full | Brief review of the mRNA vaccines COVID-19 |
title_fullStr | Brief review of the mRNA vaccines COVID-19 |
title_full_unstemmed | Brief review of the mRNA vaccines COVID-19 |
title_short | Brief review of the mRNA vaccines COVID-19 |
title_sort | brief review of the mrna vaccines covid-19 |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087898/ https://www.ncbi.nlm.nih.gov/pubmed/33932192 http://dx.doi.org/10.1007/s10787-021-00811-0 |
work_keys_str_mv | AT vitielloantonio briefreviewofthemrnavaccinescovid19 AT ferrarafrancesco briefreviewofthemrnavaccinescovid19 |